Simplifying Global Compliance
Items Tagged with 'generic'
Ranbaxy revenue increased 23 percent to $355 million for the first quarter of 2007 despite tempered growth in North America, according to the firm's earnings report released April 27. Read More
Despite Abbott Laboratories' recent decision to cut the price of one of its HIV drugs in Thailand, an activist group is questioning the drugmaker's "quid pro quo" approach of lowering drug prices in exchange for halting compulsory licensing. Read More
The FDA approved 13 different abbreviated new drug applications for generic Ambien, the agency announced this week. Read More
Language in newly signed free trade agreements (FTAs) covering data exclusivity and patent extension could delay generic drug entry in foreign markets where access to low-cost medicines is highly needed, a bipartisan group of lawmakers contends. Read More
Almost 80 percent of physicians regularly take patients' out-of-pocket costs into consideration when prescribing generic medications, according to a new study. Read More
Driven by strong product performance of its generic business line, Mylan Pharmaceuticals modified financial results for fiscal 2007, increasing its diluted earnings per share guidance range, the company said April 10. Read More
Following an eventful fourth quarter in 2006, the generic drug industry is expected to have a favorable year in 2007, Arthur Wong, an analyst with Standard & Poor’s, said in a new report. Read More
The U.S. Supreme Court will not make a determination on Ranbaxy’s challenge of the validity and enforceability of Pfizer’s main Lipitor patent, the court said. Read More
The reversal of a U.S. district court’s decision that dismissed a legal action brought by Teva Pharmaceutical to launch generic Famvir may have positive implications for generic firms taking moves to avoid at-risk launches, according to legal sources. Read More
Mylan Laboratories lost its bid to launch generic Topamax capsules and tablets after a federal court barred the company from selling its version of the epilepsy treatment prior to late 2008. Read More
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing